Clinical Trial Update: EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) [Phase 3]

View source ↗

Summary

A Phase 3 trial named EASi-KIDNEY evaluating BI 690517 in combination with empagliflozin for chronic kidney disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• BI 690517
• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Kidney Disease, Chronic | Phase 3 | Status: RECRUITING